@article{09b277dbb25d470c9e1a0c726debf99e,
title = "Correlation of Regulatory T Cell Numbers with Disease Tolerance upon Virus Infection",
abstract = "The goal of a successful immune response is to clear the pathogen while sparing host tissues from damage associated with pathogen replication and active immunity. Regulatory T cells (Treg) have been implicated in maintaining this balance as they contribute both to the organization of immune responses as well as restriction of inflammation and immune activation to limit immunopathology. To determine if Treg abundance prior to pathogen encounter can be used to predict the success of an antiviral immune response, we used genetically diverse mice from the collaborative cross infected with West Nile virus (WNV). We identified collaborative cross lines with extreme Treg abundance at steady state, either high or low, and used mice with these extreme phenotypes to demonstrate that baseline Treg quantity predicted the magnitude of the CD8 T cell response to WNV infection, although higher numbers of baseline Tregs were associated with reduced CD8 T cell functionality in terms of TNF and granzyme B expression. Finally, we found that abundance of CD44+ Tregs in the spleen at steady state was correlated with an increased early viral load within the spleen without an association with clinical disease. Thus, we propose that Tregs participate in disease tolerance in the context of WNV infection by tuning an appropriately focused and balanced immune response to control the virus while at the same time minimizing immunopathology and clinical disease. We hypothesize that Tregs limit the antiviral CD8 T cell function to curb immunopathology at the expense of early viral control as an overall host survival strategy.",
author = "Graham, {Jessica B.} and Swarts, {Jessica L.} and Edwards, {Kristina R.} and Voss, {Kathleen M.} and Richard Green and Sophia Jeng and Miller, {Darla R.} and Mooney, {Michael A.} and McWeeney, {Shannon K.} and Ferris, {Martin T.} and {de Villena}, {Fernando Pardo Manuel} and Michael Gale and Lund, {Jennifer M.}",
note = "Funding Information: Received for publication January 30, 2021. Accepted for publication February 19, 2021. Address correspondence and reprint requests to: Dr. Jennifer M. Lund, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, E5-110, Seattle, WA 98109. E-mail address: jlund@fredhutch.org ORCIDs: 0000-0001-6579-0443 (J.B.G.); 0000-0002-2251-1448 (K.R.E.); 0000-0003-1033-7670 (K.M.V.); 0000-0001-8851-7204 (R.G.); 0000-0002-0781-7254 (D.R.M.); 0000-0002-5738-5795 (F.P.-M.d.V.) 0000-0003-3284-979X (J.M.L.). This work was supported by National Institutes of Health grants U19AI100625 and R01AI141435. D.R.M., S.K.M., M.T.F., F.P.-M.d.V., M.G., and J.M.L. designed the research studies; J.B.G., J.L.S., and K.M.V. conducted experiments and acquired and analyzed data; K.R.E. and R.G. analyzed data; S.J. and M.A.M. performed data cleaning and integration; and J.B.G. and J.M.L. wrote the first draft of the manuscript. All authors read the manuscript and contributed editorial suggestions. Abbreviations used in this article: CC, collaborative cross; CC-RIX, recombinant intercross CC mice; d2, day 2; d7, day 7; d10, day 10; ROUT, robust regression and outlier removal method; Treg, regulatory T cell; UNC, University of North Carolina Chapel Hill; UW, University of Washington; VL, viral load; WNV, West Nile virus. This article is distributed under the terms of the CC BY-NC-ND Unported license. Publisher Copyright: Copyright {\textcopyright} 2021 The Authors",
year = "2021",
month = apr,
day = "1",
doi = "10.4049/immunohorizons.2100009",
language = "English (US)",
volume = "5",
pages = "157--169",
journal = "ImmunoHorizons",
issn = "2573-7732",
publisher = "NLM (Medline)",
number = "4",
}